ADMAADMA Biologics, Inc.

$4B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$118M+59.1% YoY

Gross Profit

$63M53.9% margin

Operating Income

$38M32.6% margin

Net Income

$112M95.2% margin

EPS (Diluted)

$0.46

QoQ Revenue Growth

-1.9%

Cash Flow

Operating Cash Flow

$50M

Free Cash Flow

$47M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$489M

Total Liabilities

$140M

Stockholders' Equity

$349M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$118M	$74M	+59.1%
Gross Profit	$63M	$31M	+103.7%
Operating Income	$38M	$14M	+169.3%
Net Income	$112M	-$18M	+734.2%

Revenue Segments

ADMA BioManufacturing Segment

$116M99%

Plasma Collection Centers Segment

$804,0001%

Geographic Segments

United States

$115M98%

International

$3M2%

ADMA Q4 2024 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena